NASDAQ · PRAX
Healthcare · Biotechnology
$295.51
Up+$8.60 (+3.00%)
Updated Oct 4, 2026, 1:38 AM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PRAX
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
PRAX closed at $295.51 after 19 trading sessions, down 16.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $290.13 | $298.56 | $286.00 | $295.51 | 459.61K |
| Oct 1, 2026 | $287.83 | $292.47 | $282.00 | $286.91 | 381.65K |
| Sep 30, 2026 | $284.65 | $296.27 | $282.00 | $291.23 | 710.56K |
| Sep 29, 2026 | $283.28 | $289.155 | $278.39 | $281.00 | 349.56K |
| Sep 28, 2026 | $280.78 | $292.18 | $277.905 | $285.65 | 436.73K |
| Sep 25, 2026 | $284.45 | $289.045 | $278.60 | $280.78 | 462.22K |
| Sep 24, 2026 | $281.18 | $286.38 | $276.34 | $281.79 | 535.51K |
| Sep 23, 2026 | $301.37 | $304.935 | $275.89 | $282.12 | 1.01M |
| Sep 22, 2026 | $300.19 | $312.46 | $298.40 | $300.65 | 570.24K |
| Sep 21, 2026 | $301.69 | $305.79 | $295.22 | $298.87 | 543.83K |
| Sep 18, 2026 | $312.76 | $314.005 | $295.705 | $298.95 | 829.85K |
| Sep 17, 2026 | $313.65 | $318.00 | $306.50 | $310.47 | 556.03K |
| Sep 16, 2026 | $315.22 | $321.95 | $303.88 | $308.99 | 545.77K |
| Sep 15, 2026 | $330.42 | $333.061 | $311.98 | $312.90 | 205.66K |
| Sep 14, 2026 | $337.67 | $341.705 | $328.95 | $330.55 | 375.63K |
| Sep 11, 2026 | $340.00 | $348.00 | $334.00 | $334.58 | 175.41K |
| Sep 10, 2026 | $339.60 | $347.40 | $337.31 | $338.57 | 218.84K |
| Sep 9, 2026 | $352.80 | $360.6099 | $344.03 | $345.30 | 382.96K |
| Sep 8, 2026 | $342.25 | $356.29 | $339.50 | $352.48 | 252.62K |
The latest Smart Investors Daily articles mentioning PRAX.
Company
Market Activity
Research & News
PRAX research
Company profile and research snapshot.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Needham | Buy | — |
| Aug 21, 2026 | Goldman Sachs | Buy | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 7, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Benzinga · Sep 24, 2026
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
Benzinga · Sep 24, 2026
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.
SeekingAlpha · Sep 12, 2026
Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Click for more on PRAX.
Yahoo · Sep 3, 2026
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRAX.
